Clinical Trial

Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose

Study acronym: Optimal Bup
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg). The main question it aims to answer is: will patients who are randomly assigned to the high 24 mg maintenance dose, as compared to patients randomly assigned to the standard 16 mg maintenance dose, have improved retention in buprenorphine treatment (primary outcome), improved treatment response based on use of non-prescribed opioids (secondary outcome), decreased opioid cravings (secondary outcome), and decreased risk of fatal and non-fatal opioid overdose (exploratory outcome).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-03-15; most recent amendment 2025-10-21.
Status change: Not Yet Recruiting → Recruiting 2025-03-26
Trial Details
NCT Number NCT06316830
Lead Sponsor Rhode Island Hospital
Collaborators: Brown University
Conditions Opioid Use Disorder
Enrollment 250 participants
Start Date 2025-01-06
Primary Completion 2027-08-01 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-23